Skip to NavigationSkip to content

Merck expands into US proteomics

Published on 29/10/03 at 10:48am

Merck KGaA has bought ProtoPlex, a US-based biotech company specialising in functional genomics and proteomics.

Privately owned Protoplex will be integrated into the German pharmaceutical company US subsidiary EMD Biosciences, which Merck says will help it gain access to an emerging microarray market predicted to be worth $2billion by 2008.

Financial details of the acquisition were not disclosed.

Dr Bernd Reckman, Vice President and General Manager of Merck KGaA Life Science Products Division said: "The technology and competence of ProtoPlex are a perfect fit with our own proteomics R&D programmes and will directly translate into new product offerings for our customers in the Life Sciences industry."

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches